Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Immunological Methods"
DOI: 10.1016/j.jim.2021.113197
Abstract: Since the first detection of a novel Coronavirus (SARS-CoV-2) in December 2019 in Wuhan (China), it has become crucial to assess and quantize the human humoral immune response after SARS-CoV-2 natural infection and/or vaccination. Having… read more here.
Keywords: sars cov; vaccinated subjects; convalescent; binding antibodies ... See more keywords
Abstract 1886: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1886
Abstract: In this study, we describe the characterization and validation of a diverse panel of fully human CD3-binding antibodies, including hundreds of human and cyno cross-reactive binders. We used two proof-of-concept TCE targets to demonstrate that… read more here.
Keywords: cd3; binding antibodies; panel; cd3 binding ... See more keywords
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
Sign Up to like & getrecommendations! Published in 2023 at "Toxins"
DOI: 10.3390/toxins15010060
Abstract: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004). DAXI immunogenicity was assessed in three phase 3 glabellar line studies (two placebo-controlled, single-dose studies… read more here.
Keywords: daxi; binding antibodies; daxibotulinumtoxina; daxibotulinumtoxina rtp004 ... See more keywords